{
  "ticker": "IBRX",
  "company_name": "ImmunityBio, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03563170",
      "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine",
      "status": "WITHDRAWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent",
      "start_date": "2018-05-25",
      "completion_date": "2019-08-23",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT06765954",
      "title": "Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "High-risk Prostate Cancer",
      "start_date": "2025-06-01",
      "completion_date": "2031-06-30",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT05007769",
      "title": "Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer",
      "start_date": "2021-10-31",
      "completion_date": "2026-04-30",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT06745908",
      "title": "ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NSCLC Stage IV",
      "start_date": "2025-10-01",
      "completion_date": "2029-01",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT02138734",
      "title": "A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-muscle Invasive Bladder Cancer",
      "start_date": "2014-07-21",
      "completion_date": "2038-12",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT06956547",
      "title": "Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Lymphopenia",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT02235688",
      "title": "Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Solid Tumors",
      "start_date": "2014-08",
      "completion_date": "2017-01",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT07355205",
      "title": "First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent",
      "start_date": "2026-03-31",
      "completion_date": "2032-03-31",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT04050709",
      "title": "QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor",
      "start_date": "2019-07-18",
      "completion_date": "2025-11-30",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    },
    {
      "nct_id": "NCT03647423",
      "title": "QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.",
      "status": "WITHDRAWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Chordoma, Unresectable Malignant Neoplasm",
      "start_date": "2018-08-31",
      "completion_date": "2021-12-28",
      "enrollment": 0,
      "sponsor": "ImmunityBio, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1, PHASE2": 15,
      "PHASE2": 14,
      "PHASE3": 3,
      "": 3,
      "PHASE1": 13,
      "PHASE2, PHASE3": 2
    },
    "by_status": {
      "WITHDRAWN": 14,
      "NOT_YET_RECRUITING": 4,
      "RECRUITING": 7,
      "AVAILABLE": 2,
      "COMPLETED": 8,
      "ACTIVE_NOT_RECRUITING": 6,
      "TERMINATED": 9
    },
    "active_trials": 13,
    "completed_trials": 8,
    "conditions": [
      "Advanced Solid Tumor",
      "Bladder Cancer",
      "COVID",
      "COVID-19",
      "Chordoma, Unresectable Malignant Neoplasm",
      "Colorectal Cancer Metastatic, mCRC",
      "Covid19",
      "Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma",
      "Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma",
      "Healthy Subjects",
      "Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent",
      "High-risk Prostate Cancer",
      "Kaposi's Sarcoma, HIV Positive, AIDS",
      "Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor",
      "Lymphopenia",
      "Malignant Solid Tumour",
      "Melanoma",
      "Merkel Cell Carcinoma",
      "Metastatic Pancreatic Cancer",
      "Metastatic Solid Tumor",
      "Metastatic Solid Tumors",
      "Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer",
      "Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma",
      "Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma",
      "NMIBC",
      "NSCLC Stage IV",
      "Non Hodgkin Lymphoma",
      "Non Hodgkin's Lymphoma Refractory/Relapsed",
      "Non Muscle Invasive Bladder Cancer",
      "Non Small Cell Lung Cancer",
      "Non-Hodgkin Lymphoma Refractory/ Relapsed",
      "Non-muscle Invasive Bladder Cancer",
      "Non-small Cell Lung Cancer",
      "Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent",
      "Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer",
      "Ovarian Cancer",
      "Pancreatic Cancer",
      "Pancreatic Ductal Adenocarcinoma",
      "Platinum-resistant Ovarian Cancer",
      "Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent",
      "Squamous Cell Carcinoma",
      "Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma",
      "Triple Negative Breast Cancer (TNBC)",
      "Urothelial Carcinoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:54.599486",
    "search_query": "ImmunityBio, Inc.",
    "url": "https://clinicaltrials.gov/search?term=ImmunityBio,+Inc."
  }
}